BAFFR-CAR T cells is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 1 of which is recruiting. The lead sponsor is PeproMene Bio, Inc.. Registered phase: Phase 1. Conditions studied include Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05370430 | BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL (ClinicalTrials.gov ↗) Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma |
Phase 1 | Recruiting |
| NCT04690595 | BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL (ClinicalTrials.gov ↗) Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | 1 |
| Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| PeproMene Bio, Inc. | 2 |
| Register | BAFFR-CAR T cells trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BAFFR-CAR T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BAFFR-CAR T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.